104 results about "Apoptosis Inhibition" patented technology

A recombinant adeno-associated virus expressing antisense human CYP2J2 gene and preparation method thereof are provided, the recombinant adeno-associated virus is prepared through cloning human CYP2J2 cDNA (1509 bp, which encode the protein containing 503 amino acids) from human leucocyte DNA by PCR, cotransfecting three plasmids by the calcium phosphate precipitation technique to pack and prepare the recombinant adeno-associated virus containing the antisense target gene, and purifying. The recombinant adeno-associated virus obtained from the above method can be transfected into different kinds of human tumor cell lines, inhibiting the proliferation and migration of tumor cells, promoting the apoptosis of tumor cells and suppressing the growth and metastases of tumor. Therefore, it can prove that the selective inhibitor of CYP2J2 and the recombinant adeno-associated virus expressing antisense human CYP2J2 gene are the potential medicine for treating tumor.

The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation / inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

The invention relates to lactobacillus casei with immunoregulation, anti-inflammatory and anti-cervical cancer effects. The lactobacillus casei strain is named as LH23, the preservation number is CGMCC No.16656, and the strain can be used for regulating immunity, regulating M1 / M2 macrophage balance, increasing the number of Treg cells, improving the symptoms of mouse colitis, shortening the colonlength and apoptosis of intestinal epithelial cells, inhibiting excessive secretion of proinflammatory factors (TNF-alpha, IL-1beta and IL-6) and recovering the concentration of short-chain fatty acid(SCFAs) in the intestinal tract, can resist cervical cancer, inhibit proliferation of cervical cancer HeLa cells and acetylation modification of histone, cause apoptosis of the HeLa cells and inhibitexpression of human papilloma virus HPVE6 and E7 proteins. The strain is used for preparing fermented food for inhibiting inflammatory bowel diseases and cervical cancer, and has a very wide application prospect.

There is provided a hair tonic comprising at least two of an inhibitor against 5α reductase type 2, an inhibitor against transforming growth factor β2, and an inhibitor against caspase-3; a method comprising screening for at least two of inhibition against 5α reductase type 2, inhibition against transforming growth factor β2, and inhibition against caspase-3, or comprising screening for inhibition against caspase-3 and then for apoptosis inhibition, and a hair loss inhibitor having the effect of inhibiting caspase-3, and a hair loss inhibitor having the effect of inhibiting caspase-3 and of inhibiting apoptosis.

The invention belongs to the technical field of skin light damage repair, and discloses application of exosome secreted by a human umbilical cord mesenchymal stem cell to preparation of a medicine forrepairing skin ultraviolet injury. The umbilical cord mesenchymal stem cell exosome is a natural vesica, so that the immunogenicity is lower. Meanwhile, the exosome has functions of oxidation resistance, antiinflammatory effect, proliferation, apoptosis inhibition, collagen synthesis and the like similar to the functions of a parent cell in tissue regeneration repair, and can play a role in skinprotection in multiple ways. Therefore, the exosome hopefully become an alternative strategy for decellularization treatment, and has important clinic application prospect and market transformation value in multiple skin regeneration related diseases.

The present invention provides a dye lignin derivative containing nitrogen monoxide donor, and in particular relates to a compound which is produced by ester bond connection of dye lignin (Genistein, Gen) and nitric acid ester NO (nitrogen monoxide) donor. The precursor derivative of nitrogen monoxide donor dye lignin (NO-G) with connected ester bonds is produced through chemical reaction between dye lignin (genistein) and a corresponding nitric acid ester NO donor. The ester bonds are broken in the structure through biological changes and drift out of the original drug Gen and the NO donor; NO can be slowly released to coordinate with the Gen, and the dual coordinated anti-tumor mechanism demonstrates excellent effects on apoptosis inhibition for ovary cancer and apoptosis induction of the ovary cancer.

The present invention provides a kind of medicine component capable of inhibiting the growth of lung cancer tumor through inducing the methylation of apoptosis inhibition factor. The medicine component includes oligonucleotides sequences Surkex 1 and Surkex 2 complementary with the partial promoter region sequence of apoptosis inhibition factor Survivin. The complementary combination of the sequences Surkex 1 and Surkex 2 with Survivin can reduce the expression of apoptosis inhibition factor Survivin to make tumor cell die and treat lung cancer. The action site is in the Survivin promoter region, and this is favorable to clinical medicine administration.

Provided is a pharmaceutical composition for preventing or treating neuronal diseases comprising, as an active ingredient, an exon 2-deleted AIMP2 variant (AIMP2-DX2) gene or a vector comprising the gene, and a method for treating neuronal diseases in animals other than humans, comprising administering the same to a subject in need of treatment. The pharmaceutical composition comprising, as an active ingredient, a AIMP2-DX2 gene or a vector comprising the gene has the effects of apoptosis inhibition, dyskinesia amelioration and oxidative stress inhibition and thus can be widely used for preventing and treating neuronal diseases such as Parkinson's disease and amyotrophic lateral sclerosis.

The present invention relates to the use of thioredoxin as, inter alia, a cell growth stimulator, as well as a screen for agents that are useful in reducing or preventing thioredoxin-associated apoptosis inhibition and agents that are useful in inhibiting thioredoxin stimulated cell growth.

The invention belongs to the field of biotechnology, and relates to a dual-luciferase reporter gene plasmid of a 3-UTR region of a BCL2 gene as well as a construction method and an application thereof. According to the invention, an Xba I locus of a dual-luciferase report plasmid pGL3-promoter is inserted into a 3-UTR region of an inhibitor of apoptosis gene BCL2, and the dual-luciferase reporter gene plasmid pGL3-p-BCL2-3-UTR containing the BCL2 gene in the 3-UTR region is used for detecting a regulating effect of hsa-mir-1915 to the BCL2 gene, so that the intracellular microRNA regulation is detected. The expression of the intracellular hsa-mir-1915 is detected to mark the specific intracellular microRNA expression level, so that a new research method is provided for the intracellular microRNA detection; the built dual-luciferase reporter gene plasmid in the 3-UTR region of the BCL2 gene can be used for detecting the regulating effect of the intracellular hsa-mir-1915 to the BCL2 gene; and furthermore, the dual-luciferase reporter gene plasmid in the 3-UTR of the BCL2 gene is used for the anticancer research, thereby having an excellent application foreground.

The invention discloses a compound 25hdt of protopanaxadiol derivative, that is, 20 ( R ) -25- hydroxy-dammarane type-3- Beta, 12 Beta, 20-triol, for preparing anti-cancer drugs. The compound 25hdt better inhibits tumor cell lines outside the human than PPD, ginsenoside- Rg3 and Rh2. At the same time, the compound 25hdt inhibits the tumor cells of the human from regulating, induces the tumor cells of the human to be apoptotic, inhibits the tumor cells of the human from proliferating and specifically inhibits the tumor cells of the human from growing. When the compound 25hdt is used to treat the cancers, the compound 25hdt does not cause the obvious changes of the weight of the experimental animal without any other toxic effect. Matched with other embolic chemotherapy or radiation methods to treat the cancers, the compound 25hdt can better improve the efficacy.

The invention discloses serial water-soluble hydroxycamptothecine naphthenic amino alcoholderivative. The serial water-soluble hydroxycamptothecine naphthenic amino alcohol derivative is synthesized by leading naphthenic amino alcohol methylene into a hydroxycamptothecine structure for the first time; and the hydroxycamptothecine with strong cell toxicity is decorated into the hydroxycamptothecine naphthenic amino alcohol derivative with medium cell toxicity. Therefore, the selectivity of induction of tumor cell apoptosis is improved; the situation that the hydroxycamptothecine prolinol has special hydrogenation reduction metabolic pathway in the body is found out for the first time; existing camptothecin derivatives do not have special hydrogenation reduction metabolic pathway; and active oxygen in the cell can be controlled, so as to inhibit cell proliferation, selectively induce cancer cell apoptosis, and inhibit cell inflammatory necrosis. Normal cell function is not affected.

The present invention relates to the use of thioredoxin as, inter alia, a cell growth stimulator, as well as a screen for agents that are useful in reducing or preventing thioredoxin-associated apoptosis inhibition and agents that are useful in inhibiting thioredoxin stimulated cell growth.

The invention discloses application of a PD-L1 (Programmed Death-Ligand 1) spliceosome B as a marker for instructing administration of PD-L1 / PD1 immunotherapy. Expression of three different variable spliceosomes of PD-L1 can be observed in normal and mutant colorectal cancer cell systems, and eukaryotic expression vectors of the three spliceosomes are established and transfected into tumor cells without or with low PD-L1 expression. Tests further show that in co-culture of a tumor cell system with isoform b over-expression and immune cells, apoptosis of the immune cells is promoted, secretionof immune cell factors is inhibited, inhibition of immunoreactions in bodies of patients can be reminded, and clinical sample testing shows that isoform b of PD-L1 is a monitoring target of poor prognosis of tumor.

The invention discloses application of a PCBP1 gene in preparing a radiotherapy sensitivity enhancing kit, and in particular relates to application of the PCBP1 gene in preparing a sensitivity enhancing kit for tumor radiotherapy utilizing ionizing radiation including heavy ion rays. The nucleotide sequence of the PCBP1 gene is as shown in SEQ ID NO.1 and the PCBP1 gene is established in eukaryotic expression plasmid. Together with heavy ion beams, the PCBP1 gene regulates and controls expression of the CD44v6 gene related to tumor metastasis and invasion, inhibits proliferation, migration and invasion of HeLa tumor cells, remarkably down-regulates the cell cycle regulatory protein Cyclin D1, prompts cells to generate G0 / G1 retardation, enhances the radiotherapy sensitivity of HeLa cells, up-regulates pro-apoptotic protein Tap73 and expression of the mitochondria apoptosis pathway MCL, down-regulates the apoptosis inhibition DelNp73 protein, and induces apoptosis of many HeLa cells.

The invention relates to the field of medicines, in particular to a PEDF gene composition targeted by a tumor cell folate receptor as well as a preparation method of the PEDF gene composition and a use of the PEDF gene composition. The invention constructs a folate modified PEDF gene composition which can selectively transmit coded PEDF plasmids to the tumor cell by the folate receptor highly expressed by a tumor part, so that the tumor cell is induced to die, multiplication, invasion and transfer of the tumor cell are inhibited, and therefore, the anti-tumor effect is brought into play, and a better anti-tumor effect is achieved.

The invention discloses 3-carbonyl hyperin as well as an extraction method and application thereof in the preparation of antitumor drugs. The structure of 3-carbonyl hyperin is shown as (I). The extraction method of 3-carbonyl hyperin comprises the following steps: 1) crushing roots and stems of tripterygium hypoglaucum, extracting with ethanol, and carrying out reduced pressure concentration to obtain a concentrate; 2) extracting the concentrate with petroleum ether and dichloromethane in sequence, collecting the dichloromethane extract, and concentrating the dichloromethane extract to a small volume to obtain a sample concentrate; 3) separating the sample concentrate in a high-speed counter-current chromatograph, collecting a main component, concentrating the main component under reducedpressure to a small volume, and purifying by gel column chromatography Sephadex-LH20. The compound has remarkable inhibition activity on solid tumors such as lung cancer, can promote apoptosis of tumor cells, inhibits angiogenesis, remarkably inhibits growth and metastasis of tumors in lung cancer tumor-bearing mice, and prolongs the lifetime of the mice. The invention also provides an application of 3-carbonyl hyperin in the preparation of antitumor drugs.

The invention discloses application of a substance for reducing USP1 expression in preparation of a medicine for treating children T-series acute lymphocytic leukemia. The invention discloses short hairpin RNA (Ribonucleic Acid) for forming a stem-loop structure. The short hairpin RNA is shRNA-1 or shRNA-2. The deubiquitination enzyme USP1 has the effects of inhibiting cell apoptosis and promotingcell proliferation in T-series acute lymphocytic leukemia cells, and the invention proves that inhibition of USP1 expression can promote apoptosis of tumor leukemia cells and inhibit proliferation ofleukemia cells. The invention provides a novel way for the treatment of T-series acute lymphocytic leukemia, and the deubiquitinase USP1 is expected to become a potential target for anti-leukemia treatment and has a very wide application prospect in the medical field.

The invention discloses a targeted human CD147 small molecule RNA interference sequence and the use thereof, which relate to small fragment RNA type medicines for restraining multiplication of cervical cancer cells, inducing cell apoptosis and enhancing chemical drug susceptibility of cells, and the use of the medicines. The interference sequence is as follows: SODN: CGUCAGAACACAUCAACGATT; and AODN: UCGUUGAUGUGUUCUGACGTT; the targeted human CD147 small molecule RNA interference sequence is used for multiplication of restraining human tumors, inducing apoptosis, restraining tumor invasion and metastasis and enhancing anti-tumor drug susceptibility.

The invention discloses small molecular polypeptide inhibiting MIRI and a vector and application thereof. A bioengineering technology is utilized, a section of sequence corresponding to polypeptide analogue is genetically recombined to a p3XFLAG-CMV eukaryotic expression vector; after it is proved that recombination is successful through enzyme digestion and sequential analysis, plasmid corresponding to the eukaryotic expression polypeptide analogue is transfected into myocardium cells, protein expression of polypeptide is proved through immunoblotting, and polypeptide recombination is achieved. It is proved through co-immunoprecipitation that the polypeptide analogue can promote interaction of PDCD4 and Nrf2, it is shown through cell biology experiments that the polypeptide analogue has the capacity of inhibiting myocardium cell apoptosis caused by myocardial ischemia and reperfusion injuries and the functions of resisting oxidative stress and apoptosis of the myocardium cells and inhibiting occurrence and development of MIRI.

Multifunctional compounds are provided, comprising two or more functional moieties selected from: (i) a moiety that imparts an iron chelator function; (ii) a moiety that imparts a neuroprotective function; (iii) a moiety that imparts combined antiapoptotic, neuroprotective and / or neurorestorative functions; (iv) a moiety that imparts brain MAO inhibition, preferably with little or no MAO inhibition in liver and small intestine; (v) a moiety that imparts cholinesterase inhibitory function; and (vi) a moiety that imparts an N-methyl-D-aspartic acid receptor (NMDAR) inhibition, and pharmaceutically acceptable salts and optical isomers thereof. The multifunctional compounds are useful in the treatment or prevention of diseases, disorders or conditions that can be prevented and / or treated by iron chelation therapy, and / or neuroprotection and / or neurorestoration, and / or apoptosis inhibition and / or MAO inhibition and / or cholinesterase inhibition and / or NMADR inhibition. The present invention encompasses compounds of the formulas I to VI.

The invention belongs to the field of medicines, and particularly relates to application of a neocryptolepine derivative in preparation of a medicine for treating gastric cancer. It is found that the neocryptolepine derivative Z23 can inhibit migration of gastric cancer cells, induce apoptosis of the gastric cancer cells and inhibit proliferation of the gastric cancer cells; and meanwhile, the neocryptolepine derivative Z23 basically has no toxic or side effect on normal gastric mucosa cells. Namely, compared with other neocryptolepine derivatives, cis-platinum and 5-Fu, the neocryptolepine derivative Z23 disclosed by the invention has a more remarkable effect of treating the gastric cancer and has a good application prospect.

The invention discloses siRNA interfering HIP-55 and anti-tumor application of siRNA interfering HIP-55. The nucleotide sequence of the siRNA is shown in a sequence III in a sequence table. The invention also provides a DNA molecule encoding the above siRNA. Experiments prove that HIP-55 is highly expressed in a tissue sample of a clinical lung cancer patient; and further researches show the following functions of the HIP-55: through interfering silent protein HIP-55 by RNA, tumor formation can be obviously inhibited, apoptosis is promoted, proliferation, cell cloning formation, cell migration and / or cell invasion are suppressed; therefore, siRNA interfering HIP-55 can be used for preparing products for preventing and / or treating tumors.

The present invention relates to a composition comprising an inhibitor of the expression or activity of SH3 domain containing ring finger 2 (SH3RF2) for preventing or treating cancers. More specifically, since the SH3RF2 protein, of which the expression level increases in various cancer tissues, binds to PAK4, which is a cancer-associated gene, to regulate an apoptosis inhibitory function of the PAK4 protein by ubiquitination activity of SH3RF2 RING domain, cancer cells, in which the expression of SH3RF2 is inhibited, sensitively respond to the induction of apoptosis to promote apoptosis and reduce in vivo tumorigenicity, such that the inhibitor of the expression or activity of SHRF2 can be useful as a composition for preventing or treating cancers.

The invention discloses a preparation method and application of inonotus obliquus polysaccharide. Through water extraction and alcohol precipitation, repeated freeze thawing, deproteinization, dialysis, freeze drying, affinity chromatography and other methods, a polysaccharide component with antioxidant and anti-aging functions is separated and purified from inonotus obliquus; the inonotus obliquus polysaccharide component has strong antioxidant activity; through pretreatment of the inonotus obliquus polysaccharide, etoposide-induced proliferation inhibition and apoptosis of rat aortic smoothmuscle cells can be inhibited, and etoposide-induced cellular senescence beta-galactosidase activity increase, senescence-related heterochromatin aggregation and mitochondrial membrane potential decline can be inhibited; through pretreatment of the inonotus obliquus polysaccharide, etoposide-induced increase in expression levels of p53, p21 and p16 protein and mRNA can be inhibited. The inonotus obliquus polysaccharide components prepared according to the preparation method provided by the invention has good antioxidant and anti-aging activity and has a broad application prospect as a novel anti-aging protective medicine.

The invention discloses application of nafamostat mesylate in aspect of preparing a medicine for treating colorectal cancer, and application of the combination of nafamostat mesylate and oxaliplatin in preparing a medicine for treating the colorectal cancer. Researches show that the nafamostat mesylate can be used for significantly inhibiting the growth and the proliferation of colorectal cancer cells, obviously inhibiting the growth and volume increase of the colorectal cancer, inducing apoptosis of the colorectal cancer cells and inhibiting transfer of the colorectal cancer cells, and the nafamostat mesylate, which has a significant curative effect on the colorectal cancer, can be applied to the aspect of preventing and treating the colorectal cancer. The invention not only provides novel application of the nafamostat mesylate and offers a new field for the application of the nafamostat mesylate, but also provides a novel therapeutic drug and therapeutic approach for the treatment of the colorectal cancer. Moreover, the invention also offers a novel scheme for the treatment of the colorectal cancer with the combination of the nafamostat mesylate and the oxaliplatin, and the scheme has a more obvious therapeutic effect on the colorectal cancer.

The invention discloses medical application of a compound in treatment of oral cancer by inducing apoptosis of oral cancer cells. Two chalcone derivatives are found to inhibit growth of the oral cancer by inhibiting proliferation of the oral cancer cells and inducing apoptosis of the oral cancer cells on one hand, and inhibit migration activity of the oral cancer cells on the other hand. Therefore, the two chalcone derivatives have the prospect of being developed into drugs for resisting growth of the oral cancer and resisting metastasis of the oral cancer and are used for treating the oral cancer.

The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and / or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand whichbinds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation / inhibition of target protein. Diseases or disordersthat result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

The invention belongs to the field of combination with the traditional Chinese medicine, obstetrics and gynecology and molecular pharmacology, and particularly relates to a traditional Chinese medicine composite containing angelica sinensis and having the function of treating endometriosis. The traditional Chinese medicine composite can restrain the expression level of the apoptosis inhibition factors Bc1-2 and Survivin in the endometriotic tissues of the endometriosis, and can promote the expression level of the apoptosis promoting factor Bax. The composite comprises the active ingredients in parts by weight: 1200 parts of angelica sinensis, 1000 parts of Chinese herbaceous peony, 1000 parts of cassia twig and 1000 parts of poria cocos. In the prescription, the angelica sinensis is warm in nature, and sweet and acrid in taste, can invigorate the circulation of blood, and has the function of removing stasis without disordering blood, thereby the angelica sinensis is a monarch medicament; the Chinese herbaceous peony is bitter in taste and bit in cold, not only can remove stasis by invigorating the circulation of blood, but also can remove stasis and durably dissipate hot by cooling the blood, thus the Chinese herbaceous peony is a ministerial medicament; the cassia twig is sweet, acrid and warm, and has the functions of warming blood vessel in which the blood and qi circulate, mediating Yin, activating Yang, and removing stasis; and the poria cocos is sweet and tasteless, and has the function of inducing diuresis with bland drug, thus the poria cocos is an adjuvant with the cassia twig to be good for removing defects. Various medicaments are jointly used, so that the traditional Chinese medicine composite has the functions of warming channel and dredging veins, removing stasis and generating freshness, and removing stasis and removing defects.